Leader in data-driven medicine will discuss progress in the adoption of exome and pharmacogenetic analysis

BOSTON and LAUSANNE, Switzerland, June 7, 2023 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, will attend the European Society of Human Genetics (ESHG) annual meeting in Glasgow, Scotland, UK June 10-13. While in attendance, SOPHiA GENETICS will host a symposium talking about progress in the adoption of exome and pharmacogenetics analysis. 

SOPHiA GENETICS collaborates with genetic experts to develop specialized next-generation sequencing (NGS) applications that seamlessly integrate into any laboratory workflow. At the symposium, leaders in the genetics research space will share how the analytical technology and dedicated features in the SOPHiA DDM™ Platform have enabled the accurate detection and streamlined assessment of variants associated with Rare Diseases and Pharmacogenomics. Symposium speakers will include Dr. Robert C. Akkers, molecular biologist at Result Laboratorium in the Netherlands and Dr. Berta Almoguera, research faculty at Fundación Jiménez Díaz University Hospital in Spain.

Topics of discussion will include how the SOPHiA DDM™ Platform has successfully enabled the discovery of complex variants associated with genetic diseases using exome sequencing; and how it was seamlessly integrated into routine NGS workflows for pharmacogenetic analysis.

Symposium details:

Sunday, June 11

8:30 am – 10:00 a.m. BST

Level 0, room Alsh 2

In addition to the symposium, SOPHiA GENETICS experts and executives will be on-site at booth #606 to demo the SOPHiA DDM™ Platform and talk with attendees about the company’s offerings, including the latest solution – SOPHiA CarePath™ – a module designed to take multimodal healthcare analytics to the next level.

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram. 

About SOPHiA GENETICS 
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram. 

Where others see data, we see answers. 

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS Forward-Looking Statements: 

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Media Contact: 
Kelly Katapodis
[email protected]